Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436106 | 0.75 | P2RX7 (0.41) | EPHX1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1852826 | 0.75 | ADRA2A (0.39) | ALDH1A1MAPT | |
| SCHEMBL1850641 | 0.72 | POLB (0.34) | POLBALDH1A1L3MBTL1HTTMAPT | |
| SCHEMBL9665247 | 0.71 | HTT (0.40) | POLBNPSR1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL2437157 | 0.71 | ADRA2A (0.39) | EPHX1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL4782064 | 0.70 | APLNR (0.47) | KMO | |
| SCHEMBL27964764 | 0.69 | KMO (0.36) | ALDH1A1TSHRL3MBTL1KMOSMN1; SMN2 | |
| SCHEMBL31741261 | 0.69 | ALDH1A1 (0.50) | NPSR1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL2432679 | 0.69 | ALDH1A1 (0.50) | NPSR1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL15796765 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | EPHX1 248/4885POLB 2288/4885NPSR1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.